TY - JOUR
T1 - Reutilization of doxorubicin in patients with progressive metastatic breast cancer
AU - Ro, J.
AU - Fraschini, G.
AU - Frye, D.
AU - Buzdar, A.
AU - Hortobagyi, G.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1989
Y1 - 1989
N2 - Forty patients with progressive metastatic breast cancer were retreated with doxorubicincontaining regimens, following a sustained response to previous doxorubicin-containing chemotherapy. Reintroduction of doxorubicin by intravenous bolus or by continuous infusion occured at a median of 26 mos. (range 4-114 mos.), after the last dose of doxorubicin combination chemotherapy. The dominant sites of involvement were bone, 20; visceral organs, 16 and soft tissue, 4. The response rates to doxorubicin retreatment demonstrated partial response, 30%; no change, 30% and progressive disease, 40%. There were no differences in age, time untill reuse, number of disease sites or duration of response to the first treatment between responders and non-responders to the doxorubicin retreatment. Median total dose of doxorubicin used for responders was 850 mg/m2, (from 450 to 1300 mg/m2). Two patients developed clinical evidence of congestive heart failure. In conclusion, doxorubicin-containing chemotherapy can be successfully reutilized by continuous infusion in carefully selected patients with metastatic breast cancer who initially responded to the treatment.
AB - Forty patients with progressive metastatic breast cancer were retreated with doxorubicincontaining regimens, following a sustained response to previous doxorubicin-containing chemotherapy. Reintroduction of doxorubicin by intravenous bolus or by continuous infusion occured at a median of 26 mos. (range 4-114 mos.), after the last dose of doxorubicin combination chemotherapy. The dominant sites of involvement were bone, 20; visceral organs, 16 and soft tissue, 4. The response rates to doxorubicin retreatment demonstrated partial response, 30%; no change, 30% and progressive disease, 40%. There were no differences in age, time untill reuse, number of disease sites or duration of response to the first treatment between responders and non-responders to the doxorubicin retreatment. Median total dose of doxorubicin used for responders was 850 mg/m2, (from 450 to 1300 mg/m2). Two patients developed clinical evidence of congestive heart failure. In conclusion, doxorubicin-containing chemotherapy can be successfully reutilized by continuous infusion in carefully selected patients with metastatic breast cancer who initially responded to the treatment.
UR - http://www.scopus.com/inward/record.url?scp=0024956001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024956001&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0024956001
SN - 0933-0453
VL - 2
SP - 234
EP - 238
JO - International Journal of Experimental and Clinical Chemotherapy
JF - International Journal of Experimental and Clinical Chemotherapy
IS - 4
ER -